Genitourinary Cancers

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

The concept of dose titration in patients with mRCC who fail to achieve therapeutic levels on axitinib was validated by a secondary analysis.

The FDA approved axitinib for the treatment of patients with advanced RCC who have failed to respond to another drug.

Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.

The investigational drug, tivozanib, showed improved rates of PFS in patients with advanced RCC than the already-approved sorafenib.

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

The level of C-reactive protein (CRP) expressed in the tumor specimens of patients with renal cell carcinoma (RCC) may serve as a widely available biomarker for postoperative prognosis of localized disease.

Dr. Brian I. Rini from the Cleveland Clinic Discusses the VEGF Targeted Agent Axitinib

Investigators have documented gross under-use of established recommendations for the management of high-grade noninvasive bladder cancer.

The use of nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs) is associated with an increased risk of renal cell carcinoma (RCC).

An interview with Neal D. Shore, MD, discussing expanding the scope of cystoscopy and the optical imaging agent Cysview.

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC

Dr. Brian Rini from Taussig Cancer Institute on the Progression of Advanced RCC Therapy

Dr. Brian I. Rini from the Cleveland Clinic on Standards of Care for Advanced RCC

Study results reveal that only a small fraction of patients with high-grade, noninvasive bladder cancer receive the appropriate treatment.

Dr. Brian I. Rini from the Taussig Cancer Institute Explains the Axitinib Integration Process

Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Axitinib and Sorafenib Trial Hazard Ratio

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial

Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial

The FDA announced that the prolonged use of pioglitazone (Actos) for more than 1 year has been linked to an increased risk of bladder cancer

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.

Kidney cancer resource from across the web including blogs, associations, journals, clinical trials and online CME offerings